- Home
- CEPS vs CNTB Comparison
CEPS vs CNTB Comparison
Compare CEPS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPS | CNTB |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.0M | 140.4M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CEPS | CNTB |
|---|---|---|
| Price | $10.12 | $0.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $5.88 |
| AVG Volume (30 Days) | 36.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | $11,291.47 |
| Revenue Next Year | N/A | $74.30 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.05 | $0.73 |
| 52 Week High | $10.45 | $3.82 |
Technical Indicators
Market Signals| Indicator | CEPS | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 35.11 | 35.11 |
| Support Level | $10.05 | N/A |
| Resistance Level | $10.13 | $2.84 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 14.29 | 15.67 |
Price Performance
Historical ComparisonAbout CEPS Cantor Equity Partners VI Inc. Class A Ordinary Shares
Cantor Equity Partners VI Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.